




OPEN

Author Correction:

Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Hadi AlShamaileh, Tao Wang, Dongxi Xiang, Wang Yin, Phuong Ha-Lien Tran, Roberto A. Barrero , Pei-Zhuo Zhang, Yong Li, Lingxue Kong, Ke Liu, Shu-Feng Zhou, Yingchun Hou, Sarah Shigdar & Wei Duan

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-017-05859-z>, published online 19 July 2017

This Article contains an error in the order of panels of Figure 1. Panels a, b, c, d and e should appear in the order d, e, a, b, c. The correct Figure appears below as Figure 1.

Additionally, the panels in Figures 3 and 4 are missing labels. The correct Figures appear below as Figures 2 and 3 respectively.

Finally, the Supplementary Information file contains a typographical error.

“The chimera structure features an asymmetric structure to facilitate recognition by an endogenous Dicer enzyme to cleave the chimera which results in the release of the expected 21-mer siRNA sequence [251] (Figure S1b).”

should read:

“The chimera structure features an asymmetric structure to facilitate recognition by an endogenous Dicer enzyme to cleave the chimera which results in the release of the expected 21-mer siRNA sequence (Figure S1b).”

Published online: 11 December 2020




Figure 1. EpCAM aptamer-guided RNAi effectively silenced survivin. **(a)** Specificity and efficacy of EpCAM aptamer guided RNAi in knocking down survivin mRNA. Chimera or negative control chimera were incubated with HT-29 or HEK-2913T cells for 24 hours and the total RNA was extracted for qRT-PCR analysis of survivin mRNA levels. GAPDH was used as an internal control. **(b, c)** HT-29 Tumour-bearing mice were treated with 2 nmol/mouse of PEG-labelled chimera for 48 hours. The tumours were collected for RNA extraction followed by qRT-PCR analysis of survivin mRNA expression **(b)** and 5'RACE assay **(c)**. **(d)** Effective downregulation of survivin protein via EpCAM aptamer-guided RNAi. Chimera or negative control chimera were incubated with HT-29 or HEK-2913T cells for 48 hours and the survivin protein levels were analyzed using Western blot analysis. β-actin was used as a loading control. **(e)** The bar graph shows the survivin protein levels in various treatment groups. Data shown are means ± SEM, n = 3. * $p < 0.05$, ** $p < 0.005$. NS, no statistically significant difference..




Figure 2. Survivin knockdown *in vivo* enhances 5-FU-induced apoptosis in HT-29 tumour cells. **(a)** Representative images of TUNEL apoptosis assay on dissociated HT-29 xenograft tumours after *in vivo* treatment with chimera and 5-FU. NOD/SCID mice bearing HT-29 tumours (60 mm³) were treated intravenously with 3 injections of 2 nmol/mouse of chimera with or without 3 additional treatment of 30 mg/kg of 5-FU. Two days after the final treatment, tumours were dissociated by collagenase digestion and subjected to TUNEL apoptosis assay. **(b)** Percentage of apoptotic cells in treated tumours. Data shown are means \pm SEM, n = 3. **** p < 0.001. NS, no statistically significant difference.





Figure 3. Combined chimera and 5-FU treatments improves therapeutic outcome in HT-29 tumour-bearing mice. **(a)** The graph represents the tumour volume in mice in response to various treatments as indicated. **(b)** Survival rate of mice observed over the course of various treatments. Data shown are mean \pm SEM, $n = 4-5$.

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020